Jennifer Smith-Parker spoke with Arvinas President and CEO Randy Teel in a recent episode of Denatured presented by Arvinas, according to a Jul. 30 episode. The discussion focused on the strategic discipline and leadership required to refocus a biotech or pharmaceutical company on an early-stage pipeline after the company's lead asset is outlicensed, discontinued, or otherwise removed from development.
Teel described how Arvinas evaluates opportunities in areas such as neurology and additional oncology indications as part of its approach to broadening its pipeline. He outlined the company's framework for target selection and maintaining portfolio balance.
The conversation also addressed the strategic value of outlicensing assets, navigating therapeutic nuances when entering new research areas, and applying proven mechanisms in new indications. Teel said these factors are key considerations when companies face inflection points related to their main products.
Smith-Parker hosted the discussion as Director of Insights at BioSpace. The episode was presented in partnership with Arvinas.
A disclaimer noted that "the views expressed in this discussion by guests are their own and do not represent those of their organizations."
